B
B. J. Fessler
Researcher at University of Alabama
Publications - 19
Citations - 2279
B. J. Fessler is an academic researcher from University of Alabama. The author has contributed to research in topics: Lupus erythematosus & Systemic lupus erythematosus. The author has an hindex of 16, co-authored 19 publications receiving 2101 citations. Previous affiliations of B. J. Fessler include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P. Tashkin,Robert Elashoff,Philip J. Clements,Jonathan G. Goldin,Michael D. Roth,Daniel E. Furst,Edgar Arriola,Richard M. Silver,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fredrick M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,B. J. Fessler,Naomi F. Rothfield,Mark L. Metersky +30 more
TL;DR: One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.
Journal ArticleDOI
Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study
Dinesh Khanna,Dinesh Khanna,Philip J. Clements,Daniel E. Furst,Yun Chon,Robert Elashoff,Michael D. Roth,Mildred Sterz,Joannie Chung,John FitzGerald,James R. Seibold,John Varga,Arthur C. Theodore,Fredrick M. Wigley,Richard M. Silver,Virginia D. Steen,Maureen D. Mayes,M. Kari Connolly,B. J. Fessler,Naomi F. Rothfield,Kamal K. Mubarak,Jerry A. Molitor,Donald P. Tashkin +22 more
TL;DR: The SF-36 complements the BDI and VAS scores for breathing in scleroderma lung disease and is variably correlated with results of pulmonary function tests, suggesting that theSF-36 should be included as an outcome measure in intervention trials in this population.
Journal ArticleDOI
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events
K. T. Ho,Chul Ahn,Graciela S. Alarcón,Bruce A. Baethge,F. K. Tan,Jeffrey M. Roseman,Holly M. Bastian,B. J. Fessler,Gerald McGwin,Luis M. Vilá,J. Calvo-Alén,John D. Reveille +11 more
TL;DR: Smoking and disease activity emerged as important determinants in the occurrence of thrombotic events in patients with systemic lupus erythematosus and comprehensive treatment strategies should be directed to both smoking cessation and control of disease activity.
Journal ArticleDOI
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Dinesh Khanna,Xiaohong Yan,Donald P. Tashkin,Daniel E. Furst,Robert Elashoff,Michael D. Roth,Richard M. Silver,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fredrick M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,B. J. Fessler,Naomi F. Rothfield,Mark L. Metersky,Philip J. Clements +30 more
TL;DR: One year of treatment with CYC leads to an improvement in HRQOL in patients with scleroderma lung disease, and differences in the HAQ DI,SF-36 role physical, general health, vitality, role emotional, mental health scales, and SF-36 mental component summary (MCS) score were statistically significant for CYC versus placebo.
Journal ArticleDOI
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
Arnold E. Postlethwaite,Kee Wong Weng,Philip J. Clements,Soumya Chatterjee,B. J. Fessler,Andrew H. Kang,Joseph H. Korn,Maureen D. Mayes,Peter A. Merkel,Jerry A. Molitor,Jerry A. Molitor,Larry W. Moreland,Naomi F. Rothfield,Robert W. Simms,Edwin A. Smith,Robert Spiera,Virginia D. Steen,Kenneth J. Warrington,Barbara White,F. M. Wigley,Daniel E. Furst +20 more
TL;DR: Although the results from this trial did not meet the primary outcome goals, the findings from exploratory analyses indicated that CI treatment may benefit patients with late-phase dcSSc.